Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 25;12(10):2174.
doi: 10.3390/biomedicines12102174.

Searching for a Novel HLA-Cw6-Linked Cardiometabolic Endotype in Psoriatic Disease

Rubén Queiro  1   2   3   4 , Pablo González Del Pozo  1 , Paula Alvarez  1 , Norma Calleja  1 , Ignacio Braña  1 , Marta Loredo  1 , Estefanía Pardo  1 , Stefanie Burger  1 , Sara Alonso  1 , Mercedes Alperi  1
Affiliations

Searching for a Novel HLA-Cw6-Linked Cardiometabolic Endotype in Psoriatic Disease

Rubén Queiro et al. Biomedicines. .

Abstract

Background/objectives: In recent years, a possible connection between HLA-Cw6 and a distinctive cardiometabolic (CM) profile in patients with psoriatic disease (PsD) has been proposed, although there is still little support for this. Our aim was to further investigate this possible association by studying a large population of PsD patients.

Methods: For this study, three different cohorts of patients with PsD were analyzed: two with a majority of cutaneous psoriasis, pooled n: 600, and a third with only psoriatic arthritis-PsA-cases, n: 340. Potential relationships between HLA-Cw6 and the different CM risk factors (hypertension, diabetes, obesity, dyslipidemia) were analyzed using univariate and multivariate regression models, while the final net effect was assessed using fixed- or random-effects meta-analyses, as appropriate.

Results: In the PsA cohort, no association was detected between HLA-Cw6 carriership and any of the CM comorbidity factors. In psoriasis cohorts, after correcting for age, sex, disease duration, and arthritis, HLA-Cw6 carriers had a reduced diabetes risk (OR 0.49, 95%CI: 0.26-0.91, p = 0.026). This latter effect was confirmed by a fixed-effects meta-analysis of the included cohorts (pooled OR: 0.50, 95%CI: 0.27-0.90).

Conclusions: This work demonstrates a potential protective effect of the HLA-Cw6 allele on the risk of diabetes in PsD. Our findings together with those of others seem to confirm the existence of a novel HLA-Cw6-linked cardiometabolic endotype in this disease.

Keywords: HLA-Cw6; cardiometabolic comorbidity; diabetes; psoriasis; psoriatic arthritis; psoriatic disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
A forest plot of the relationship between HLA-Cw6 and hypertension risk. Pooled ORs are presented for both the fixed-effects and random-effects models. Psor2: psoriatic arthritis cohort. Psor3: pooled psoriasis cohorts. See text for details.
Figure 2
Figure 2
A forest plot of the relationship between HLA-Cw6 and diabetes risk. Pooled ORs are presented for both the fixed-effects and random-effects models. Psor2: psoriatic arthritis cohort. Psor3: pooled psoriasis cohorts. See text for details.
Figure 3
Figure 3
A forest plot of the relationship between HLA-Cw6 and obesity. Pooled ORs are presented for both the fixed-effects and random-effects models. Psor2: psoriatic arthritis cohort. Psor3: pooled psoriasis cohorts. See text for details.
Figure 4
Figure 4
Pooled ORs are presented for both the fixed-effects and random-effects models. Psor2: psoriatic arthritis cohort. Psor3: pooled psoriasis cohorts. See text for details.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Scarpa R., Caso F., Costa L., Peluso R., Spanò A., Lubrano E., Del Puente A., Moll J.M. Psoriatic Disease: Clinical Staging. J. Rheumatol. Suppl. 2015;93:24–26. doi: 10.3899/jrheum.150629. - DOI - PubMed
    1. Perez-Chada L.M., Merola J.F. Comorbidities associated with psoriatic arthritis: Review and update. Clin. Immunol. 2020;214:108397. doi: 10.1016/j.clim.2020.108397. - DOI - PubMed
    1. Caso F., Chimenti M.S., Navarini L., Ruscitti P., Peluso R., Girolimetto N., Del Puente A., Giacomelli R., Scarpa R., Costa L. Metabolic Syndrome and psoriatic arthritis: Considerations for the clinician. Expert. Rev. Clin. Immunol. 2020;16:409–420. doi: 10.1080/1744666X.2020.1740593. - DOI - PubMed
    1. Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int. J. Mol. Sci. 2017;19:58. doi: 10.3390/ijms19010058. - DOI - PMC - PubMed
    1. Piaserico S., Orlando G., Messina F. Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways. Int. J. Mol. Sci. 2022;23:9063. doi: 10.3390/ijms23169063. - DOI - PMC - PubMed

LinkOut - more resources